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Abstract 
Motivation: Prediction of drug resistance and identification of its mechanisms in bacteria such as Mycobacterium 
tuberculosis, the etiological agent of tuberculosis, is a challenging problem. Solving this problem requires a transpar-
ent, accurate, and flexible predictive model. The methods currently used for this purpose rarely satisfy all of these 
criteria. On the one hand, approaches based on testing strains against a catalogue of previously identified mutations 
often yield poor predictive performance; on the other hand, machine learning techniques typically have higher 
predictive accuracy, but often lack interpretability and may learn patterns that produce accurate predictions for the 
wrong reasons. Current interpretable methods may either exhibit a lower accuracy or lack the flexibility needed to 
generalize them to previously unseen data.
Contribution: In this paper we propose a novel technique, inspired by group testing and Boolean compressed sens-
ing, which yields highly accurate predictions, interpretable results, and is flexible enough to be optimized for various 
evaluation metrics at the same time.
Results: We test the predictive accuracy of our approach on five first-line and seven second-line antibiotics used for 
treating tuberculosis. We find that it has a higher or comparable accuracy to that of commonly used machine learning 
models, and is able to identify variants in genes with previously reported association to drug resistance. Our method 
is intrinsically interpretable, and can be customized for different evaluation metrics. Our implementation is available at 
github. com/ hooma nzabe ti/ INGOT_ DR and can be installed via The Python Package Index (Pypi) under ingotdr. This 
package is also compatible with most of the tools in the Scikit-learn machine learning library.
Keywords: Drug resistance, Interpretable machine learning, Group testing, Integer linear programming, Rule-based 
learning, Whole-genome sequencing
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Background
Drug resistance is the phenomenon by which an infec-
tious organism (also known as pathogen) develops resist-
ance to one or more drugs that are commonly used 
in treatment [1]. In this paper we focus our attention 
on Mycobacterium tuberculosis (MTB), the etiological 
agent of tuberculosis, which is the largest single infec-
tious agent killer in the world today, responsible for over 
10 million detected cases and approximately 1.4 million 
deaths only in 2019 [2].
The development of resistance to common drugs used 
in treatment is a serious public health threat, not only 
in low and middle-income countries, but also in high-
income countries where it is particularly problematic 
in hospital settings [3]. It is estimated that, without the 
urgent development of novel antimicrobial drugs, the 
total mortality due to drug resistance will exceed 10 
million people a year by 2050, a number exceeding the 
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Existing models for predicting drug resistance from 
whole-genome sequencing (WGS) data broadly fall into 
two classes. The first, which we refer to as “catalogue 
methods,” involves testing the WGS data of an isolate for 
the presence of point mutations (most often single-nucle-
otide polymorphisms, or SNPs) associated with known 
drug resistance. These mutations are typically identified 
via a microbial genome-wide association study (GWAS) 
and may be confirmed with a functional genomics study. 
If at least one previously identified mutation is present, 
the isolate is declared to be resistant [5–9]. While these 
methods are simple to understand and apply, they often 
suffer from poor predictive accuracy [10], especially in 
identifying new resistance mechanisms or predicting 
resistance to rarely used drugs.
The second class, which we refer to as “machine learn-
ing methods”, seeks to infer the drug resistance of an iso-
late by training complex models directly on WGS and 
drug susceptibility test (DST) data [11–13]. Such meth-
ods tend to result in highly accurate predictions at the 
cost of flexibility and interpretability - specifically, they 
typically provide only limited, if any, insights into the 
drug resistance mechanisms involved, and often do not 
impose explicit limits on the predictive model’s complex-
ity. Learning approaches based on deep neural networks 
[13, 14] are an example of very accurate but very complex 
“black-box” models of drug resistance.
In this paper we propose a novel method, based on 
the group testing problem [15] and Boolean compressed 
sensing (CS), for the prediction of drug resistance. CS is 
a mathematical technique for sparse signal recovery from 
under-determined systems of linear equations [16], and 
has been successfully applied in many application areas 
including digital signal processing [17, 18], MRI imaging 
[19], radar detection [20], and computational uncertainty 
quantification [21, 22]. Under a sparsity assumption on 
the unknown signal vector, it has been shown that CS 
techniques enable recovery from far fewer measurements 
than required by the Nyquist–Shannon sampling theo-
rem [23]. Boolean CS is a modification of the CS prob-
lem, replacing linear algebra over the real numbers with 
Boolean algebra over binary numbers [24], which has 
been successfully applied to various forms of non-adap-
tive group testing [24–26].
Our approach, INterpretable GrOup Testing for Drug 
Resistance (INGOT-DR), combines the flexibility and 
interpretability of catalogue methods with the accu-
racy of machine learning methods. More specifically, 
INGOT-DR is capable of recovering interpretable rules 
for predicting drug resistance that both result in a high 
classification accuracy as well as provide insights into 
the mechanisms of drug resistance. We compare the 
performance of INGOT-DR with that of standard and 
state-of-the-art machine learning and rule-based learn-
ing methods which have been previously used for geno-
type-phenotype prediction on MTB data. These methods 
are logistic regression (LR) [27], random forests (RF) [28], 
Support Vector Machines (SVM) [29], and KOVER [30]. 
The comparison covers the prediction of drug resistance 
for twelve drugs, of which five are first-line and seven are 
second-line drugs. INGOT-DR displays a competitive 
performance while maintaining interpretability, flexibil-
ity, and accurately recovering many of the known mecha-
nisms of drug resistance.
Methods
We present our methodology as follows.  “Group test-
ing and Boolean compressed sensing” and  “From group 
testing to interpretable classiffication” introduce the 
group testing problem, and discuss how group testing 
can be combined with compressed sensing to deliver an 
interpretable predictive model. “Our approach leads to a 
refined ILP formulation” introduces substantial modifica-
tions to a previously published method, which are needed 
to produce an accurate and flexible classifier that can be 
tuned for specific evaluation metrics and tasks. “Opti-
mizing different target metrics such as the sensitivity 
and the specificity” describes the tuning process required 
to provide the desired trade-off between sensitivity and 
specificity in a model’s predictions.
Group testing and Boolean compressed sensing
We frame the problem of predicting drug resistance 
given sequence data as a group testing problem, origi-
nally introduced in [15]. This approach for detecting 
defective members of a set was motivated by the need to 
screen a large population of soldier recruits for syphilis in 
the United States during the World War II. The screen-
ing, performed by testing blood samples, was costly due 
to the low numbers of infected individuals. To make the 
screening more efficient, Robert Dorfman suggested 
pooling blood samples into specific groups and testing 
the groups instead. A positive result for the group would 
imply the presence of at least one infected member. The 
problem then becomes one of finding the subset of indi-
viduals whose infected status can explain all the positive 
results without invalidating any of the negative ones.
In this setting, the design matrix encodes the individu-
als tested in each group, the outcome vector describes the 
result of each test, and the solution, obtained from a suit-
able algorithmic procedure, is a {0, 1}-valued vector rep-
resenting the infection status of the individuals [24, 31]. 
Since the fraction of infected individuals is assumed to be 
small, the solution vector is sparse and can be recovered 
with Boolean CS. The importance of this observation lies in 
the fact that the result of solving the Boolean CS problem 
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can also be interpreted as a sparse set of rules for determin-
ing the status of each sample in other data mining contexts 
[24]. We summarize this correspondence in our context in 
Table 1 below, and use the context-specific interpretation 
throughout the rest of this paper.
Mathematically, the problem with m isolates and n 
SNPs can be described by the Boolean design matrix 
A ∈ {0, 1}m×n , where Aij indicates the presence/absence 
status of SNP j in the i-th isolate, and the Boolean outcome 
vector y ∈ {0, 1}m , where yi represents the drug resistance 
phenotype of the i-th isolate. Let us define the relevance 
vector w ∈ {0, 1}n in such a way that wj = 1 if and only if 
the j-th SNP is relevant to drug resistance.
The key assumption is that one or more SNPs relevant to 
drug resistance can cause the isolate to be drug-resistant, 
whereas an isolate with no such SNP will be drug-sensi-
tive. This is an assumption commonly made in the litera-
ture, and is precisely the same as the key assumption of 
group testing, which is that the presence of one or more 
infected individuals leads to a positive test, while a test with 
no infected individuals comes out negative (we note that 
these assumptions only hold in the absence of noise). In 
fact, although our group is the first one, to our knowledge, 
to make the connection between group testing and drug 
resistance prediction, a previously published method for 
this task [32] corresponds almost perfectly to the Definite 
Defectives algorithm used in group testing [33].
Under this assumption, the outcome vector satisfies the 
relationship
where ∨ and ∧ are the Boolean OR and AND operators, 
respectively. Using the definition of Boolean matrix-vec-
tor multiplication, this can be equivalently written
If the status vector w satisfying Eq. (1) is assumed to be 




Aij ∧ wj ∀ 1 ≤ i ≤ m,
(1)y = A ∨ w.
finding w becomes an instance of the sparse Boolean vec-
tor recovery problem:
where ‖w‖0 , called the ℓ0-norm of w, is the number of 
non-zero entries it contains.
The combinatorial optimization problem (2) is well-
known to be NP-hard [34]. In [24, 35] an equivalent for-
mulation of (2) via 0–1 integer linear programming (ILP) 
is proposed, in which the ℓ0-norm is replaced by the con-
vex ℓ1-norm, equivalent to it over binary vectors, and the 
Boolean matrix-vector product is replaced with equiva-
lent linear constraints. We recapitulate their formulation 
here:
Here, P := {i : yi = 1} and Z := {i : yi = 0} are the sets 
of positive (drug-resistant) and negative (drug-sensitive) 
isolates, respectively, and AS denotes the submatrix of A 
whose row indices are in the given subset S. In this for-
mulation, the objective is to minimize the number of 
SNPs inferred to be relevant to drug resistance. The first 
constraint then ensures that each SNP is classified as 
either relevant or irrelevant, the second one ensures that 
the drug-resistant isolates have at least one relevant SNP 
present, and the third one ensures that the drug-sensitive 
isolates do not have any such SNPs, in line with our key 
assumption. This NP-hard problem formulation can fur-
ther be made tractable for linear programming by relax-
ing the Boolean constraint on w in (3) to 0 ≤ wj ≤ 1 for 
all 1 ≤ j ≤ n [24].
Because the Boolean CS problem is based on Boolean 
algebra, the conditions on the Boolean matrices A that 
guarantee exact recovery of k-sparse status vectors 
(vectors with at most k 1’s) via such linear program-
ming relaxations are quite stringent, and differ from 






s.t. w ∈ {0, 1}n
APw ≥ 1
AZw = 0
Table 1 Correspondence between group testing and the drug resistance prediction problem
Term Meaning: group testing Meaning: drug resistance Notation Domain
Row dimension Number of tests Number of isolates m N
Column dimension Population size Number of SNPs/variants n N
Sparsity/rule size Infection prevalence Number of relevant SNPs k {0, 1, . . . , n}
Design matrix Test membership Genotype matrix A {0, 1}m×n
Outcome vector Test result vector Phenotype/label vector y {0, 1}m
Status vector Infected/uninfected Relevant/irrelevant to DR w {0, 1}n
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those of standard CS. Specifically, in order to hold, 
these guarantees require the matrix A to be k-disjunct, 
i.e. for any sum of at most k of its columns to not be 
greater than or equal to any other column. As we have 
no control over A in our setting, no such recovery guar-
antees can be provided.
In [24], the combinatorial problem (3) is augmented 
with slack variables and a regularization term to trade 
off between the sparsity of w on the one hand, and the 
discrepancy between the predicted and the actual out-
come vector on the other hand. With these modifica-
tions, the formulation becomes: 
 where  > 0 is a regularization parameter and ξ is the so-
called slack vector. Taking this formulation as a starting 
point, we introduce several refinements in “Our approach 
leads to a refined ILP formulation”.
From group testing to interpretable classification
As described in the previous section, the solution to 
the ILP (4) can be seen as an interpretable rule-based 
classifier in contexts beyond group testing. The status 
vector w naturally encodes the following rule: If any 
feature f with wf = 1 is present in the sample, clas-
sify it as positive; otherwise, classify it as negative. 
More formally, assume that we have a labelled dataset 
D = {(x1, y1), . . . , (xm, ym)} , where the xi ∈ X := {0, 1}n 
are n-dimensional binary feature vectors and the 
yi ∈ {0, 1} are the binary labels. The feature matrix A is 
defined via Aij = (xi)j (the j-th component of the i-th 
feature vector). If ŵ is the solution of ILP (4) for this 
matrix A and the outcome vector y = (yi)mi=1 , we define 
the classifier ĉ : X → {0, 1} via
What makes this classifier interpretable is that it explic-
itly depends on the presence or absence of specific fea-








(4b)s.t. w ∈ {0, 1}n
(4c)0 ≤ ξi ≤ 1, i ∈ P
(4d)0 ≤ ξi, i ∈ Z
(4e)APw + ξP ≥ 1
(4f )AZw − ξZ = 0,
(5)ĉ(x) = x ∨ ŵ.
Our approach leads to a refined ILP formulation
The formulation of the ILP (4) is designed to provide, via 
the parameter  , a trade-off between the sparsity of a rule 
and the total slack, a quantity that resembles (but does not 
equal) the training error. We now describe a refinement of 
this formulation that directly encodes the different types of 
error, which provides more flexibility during the training 
process by allowing us to optimize a more precise objec-
tive function that is particularly suitable to the application 
at hand.
As was done in the previous section, we assume that ĉ 
is the binary classifier obtained by training with a Boolean 
feature matrix A and its corresponding label vector y. We 
further refer to a misclassified training sample as a false 
negative if it has label 1 (is in P ), and as a false positive if 
it has label 0 (is in Z ). In the drug resistance setting, a false 
negative would mean that we incorrectly predict a drug-
resistant isolate to be drug-sensitive, while a false positive 
would mean that we predict a drug-sensitive isolate to be 
drug-resistant.
We begin by noting that in the ILP (4), each entry of ξP 
must take on a value of 0 or 1, and a value of 1 corresponds 
to a false negative for ĉ . This follows from the fact that A is a 
binary matrix and w is a binary vector, so the optimal ξP is 
also a binary vector (since  > 0) , and therefore
where we use FN to denote the number of false negatives.
However, ξZ in the ILP (4) can take on integer values 
greater than 1 corresponding to false positives for ĉ . To be 
able to express the number of false positives, denoted FP, 
we modify the constraints (4d) and (4f) by also setting




j=1 Aij and Ai is the ith row of A.
After these modifications, (8) ensures that ξi = 1 if 
Aiw > 0 , while the presence of ξZ in the objective function, 
with  > 0 , ensures that ξi = 0 if Aiw = 0 , for any i ∈ Z . 
We now also get
To provide additional flexibility for situations where false 
positives and false negatives are valued differently, we 
further split the regularization term into two: one for the 





T ξP =: FN,
(7)ξi ∈ {0, 1}, i ∈ Z





T ξZ = FP.
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The general form of the new ILP is now as follows:
In this new formulation, P and Z control the trade-off 
between the false positives and the false negatives, and 
jointly influence the sparsity of the rule. In the following 
section we describe how this formulation can be further 
tailored to optimize different evaluation metrics, such as 
the sensitivity and the specificity of the predictor.
Optimizing different target metrics such as the sensitivity 
and the specificity
Since the ILP formulation in (11) provides us with 
direct access to the two components of the training 
error as well as the sparsity (rule size), we may modify 
the classifier to optimize a variety of target metrics by 
transforming some of the objective function compo-
nents into constraints and optimizing the remaining 
ones.
For instance, assume that we would like to train the 
classifier ĉ to maximize the sensitivity at a given mini-
mum specificity t̄ and maximum rule size k. Recall that
From Eqs. (10), (12) and the definition of Z , we get the 
constraint
 Also, to restrict the maximum rule size to k we can use 
the constraint
Our objective is to maximize the sensitivity, which is 
equivalent to minimizing 
∑
i∈P ξi by Eqs. (13) and (6). In 
addition, by incorporating Eqs. (14) and (15), the ILP (11) 



















s.t. w ∈ {0, 1}n
ξ ∈ {0, 1}m
APw + ξP ≥ 1


















⇐⇒ 1T ξZ ≤ (1− t̄)|Z|.
(15)1Tw ≤ k
The maximum specificity at given sensitivity and rule size 
can be found analogously. In a similar way, one can mini-
mize a weighted average of rule size and false positive 
rate at a given maximum false negative rate (minimum 
sensitivity), or vice versa.
Implementation
Existing methods used for comparison with INGOT‑DR
To ensure a fair comparison, we use three popular 
machine learning methods used for drug resistance 
prediction: random forests (RF) [28], logistic regres-
sion (LR) [27], and support vector machines (SVM) 
[29]. The use of RF is motivated by its flexibility and 
its many successful applications in computational biol-
ogy and genomics [36, 37]. The use of LR is based on 
its excellent performance in drug resistance prediction 
for MTB in comparison to other methods [38]. The use 
of SVM is motivated by its excellent performance in a 
comparison of drug resistance prediction for multiple 
bacterial pathogens [30]; we use it with a linear kernel 
for simplicity, although other kernels are often used 
[39]. For LR and SVM, we consider the ℓ1 and ℓ2 regu-
larizations, which correspond to penalizing the sum of 
the absolute values and the Euclidean norm of the coef-
ficients, respectively.
We also use, to our knowledge, the only other inter-
pretable machine learning method for drug resist-
ance prediction, KOVER [30]. All the methods except 
KOVER are implemented in the Python program-
ming language [40]. Although KOVER can provide 
rule-based classifiers from two algorithms: Classifi-
cation and Regression Trees (CART) and Set Cover-
ing Machine (SCM), we only consider the latter as it 
is the main innovation of KOVER [41], and the two 
algorithms yield very similar accuracy [30]. We use the 
Scikit-learn [42] implementation for the machine learn-
ing models—RandomForestClassifier for RF, LogisticRe-
gression for LR, and LinearSVC for SVM. We also use 
KOVER version 2.0 [43], and harness the Python API to 
the CPLEX optimizer, version 12.10.0 [44], through the 






s.t. w ∈ {0, 1}n
ξ ∈ {0, 1}m,
APw + ξP ≥ 1
αiξi − Aiw ≥ 0 ∀ i ∈ Z
1Tw ≤ k
1T ξZ ≤ (1− t̄)|Z|.
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Data
We combine data from the Pathosystems Resource 
Integration Center (PATRIC) [47] and the Relational 
Sequencing TB Data Platform (ReSeqTB) [48]. This 
results in 8000 isolates together with their resistant/sus-
ceptible status for twelve drugs, including five first-line 
(rifampicin, isoniazid, pyrazinamide, ethambutol, and 
streptomycin) and seven second-line drugs (kanamycin, 
amikacin, capreomycin, ofloxacin, moxifloxacin, cipro-
floxacin, and ethionamide) [49, 50]. The whole-genome 
sequencing data for these 8000 isolates, in the form of 
paired FASTQ files, are downloaded from the European 
Nucleotide Archive [51] and the Sequence Read Archive 
[52]. The accession numbers used to obtain the data in 
our study are: ERP[000192, 000520, 006989, 008667, 
010209, 013054], PRJEB[10385, 10950, 14199, 2358, 
2794, 5162, 9680], PRJNA[183624, 235615, 296471], and 
SRP[018402, 051584, 061066].
In order to transform the raw sequencing data into 
variant calls, we use a pipeline similar to that used in pre-
vious work [50, 53]. We use the BWA software [54], spe-
cifically, the BWA-MEM program, for the mapping. We 
then call the single-nucleotide polymorphisms (SNPs) of 
each isolate with two different pipelines, SAMtools [55] 
and GATK [56], and take the intersection of their calls 
to ensure reliability. The final dataset, which includes the 
position as well as the reference and alternative allele for 
each SNP [50], is used as the input to our machine learn-
ing tools.
Starting from this input we create a binary feature 
matrix as described in “From group testing to interpret-
able classiffication”. For each drug, we only consider the 
isolates with a status for this drug. We group all the SNPs 
in perfect linkage disequilibrium (LD) [57], i.e. sharing 
identical presence/absence patterns in those isolates, 
into a single feature that we call a SNP group. This rep-
resentation does not affect the predictive accuracy of any 
machine learning methods, but helps create a consist-
ent feature importance score for the non-interpretable 
ones. In KOVER, at most one SNP in a SNP group can be 
selected to be part of a rule, and the remaining SNPs in 
the group are labelled equivalent [41]; we adopt this con-
vention here. The number of labeled and drug-resistant 
isolates, as well as the number of SNPs and SNP groups 
for each drug, is shown in Table 2.
Splitting the data into a training and testing set; tuning 
the hyper‑parameters
To evaluate our classifier we use a random stratified 
train-test split, where the training set contains 80% and 
the testing set contains 20% of data. For hyper-parameter 
tuning, Scikit-learn provides two main approaches: grid 
search and randomized search cross-validation. KOVER 
is also equipped with two tuning techniques, K-fold 
cross-validation and risk bound selection. To make 
the comparison as consistent as possible, we use 5-fold 
cross-validation for KOVER and grid search with 5-fold 
cross-validation for all the other models. During cross-
validation, balanced accuracy is used as the model selec-
tion metric for all the models except KOVER; to the best 
of our knowledge, KOVER does not provide the option to 
change the model selection metric.
Evaluating the models’ performance
Evaluating the performance of an interpretable predic-
tive model can be challenging. While most evaluation 
methods focus on predictive accuracy, it is essential to 
assess the model’s interpretability as well. Although there 
is no consensus definition of interpretability, [58] suggest 
that an interpretable method should be able to provide 
an acceptable predictive accuracy while being easy to 
understand and provide meaningful insights to its audi-
ence. Adopting their idea, we evaluate the performance 
of our approach and the competitor methods using three 
metrics: 
1. Predictive accuracy, measured via the balanced accu-
racy, 
2. Simplicity, measured via the number of features 
(SNPs) in the trained model.
3. Insight generation, measured via the relevance of the 




Table 2 Summary statistics for our dataset, with a line 
separating first-line and second-line drugs
Drug # of isolates # of 
resistant 
isolates
# of SNPs # of SNP groups
Ethambutol 6096 1407 597,133 55,164
Isoniazid 7734 3445 642,373 65,090
Pyrazinamide 3858 754 281,432 33,942
Rifampicin 7715 2968 646,855 65,379
Streptomycin 5125 2104 542,640 45,037
Kanamycin 2436 697 391,708 21,513
Amikacin 2033 573 141,952 17,103
Capreomycin 1991 552 341,935 15,389
Ofloxacin 2911 800 407,235 23,905
Moxifloxacin 961 129 97,700 11,927
Ciprofloxacin 443 37 43,950 5,563
Ethionamide 1516 498 344,960 15,145
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This evaluation process is demonstrated in detail in “The 
comparison between interpretable and non-interpretable 
models” and “Results”.
The comparison between interpretable 
and non‑interpretable models
The overall pipeline consists of SNP calling and SNP 
grouping as described in “Data”, hyper-parameter tuning 
as described in “Splitting the data into a training and test-
ing set; tuning the hyper-parameters”, and model training 
and testing using the balanced accuracy as the metric as 
described in “Evaluating the models’ performance”. This 
addresses the first evaluation criterion, the predictive 
accuracy.
To evaluate model simplicity, we investigate the SNPs 
selected by each model. For the rule-based classifi-
ers, we ensure a low model complexity, and therefore a 
higher interpretability, by training both INGOT-DR and 
KOVER with the same maximum allowed rule size (num-
ber of SNPs used), k. By default, INGOT-DR also has a 
(training) specificity lower bound of t̄ = 90% , via the con-
straint explained in “Optimizing different target metrics 
such as the sensitivity and the specificity”. We evaluate 
the simplicity of the remaining models by counting the 
SNPs with non-zero coefficients for LR and SVM, and the 
SNPs with a non-zero importance according to Scikit-
learn for RF.
Lastly, to evaluate and fairly compare the models’ 
ability to generate insights, we compare the top k most 
important SNPs for each one [59]. For both INGOT-DR 
and KOVER, we simply evaluate the k or fewer SNPs 
used in each rule. Since the other machine learning 
methods are not inherently interpretable, we extract the 
SNP importance values using the Shapley additive expla-
nation (SHAP) algorithm [60], a model-agnostic method 
for making explainable predictions rooted in game the-
ory. This algorithm, implemented in the SHAP Python 
package, version 0.37.0 [61], provides the guaranteed 
unique solution satisfying three fairness conditions. We 
apply TreeExplainer for RF and LinearExplainer for LR 
and SVM, and select the k SNPs with the highest impor-
tance. We use k = 20 in all our experiments.
Results
INGOT‑DR produces accurate predictive models
The performance of INGOT-DR compared to that of the 
other methods in terms of the balanced accuracy is sum-
marized in Table 3, and Fig. 1 separately shows the sen-
sitivity and specificity. Overall, INGOT-DR outperforms 
all other models on 4/12 of the drugs, obtains the best 
performance (tied with KOVER) on an additional drug, 
and achieves a balanced accuracy within 5% of the best 
one for the remaining 7/12 drugs. SVM-l1 achieves the 
best balanced accuracy in 4/12 of the drugs, while LR-l1 
and KOVER obtain the best balanced accuracy in 2/12 
drugs each. Furthermore, INGOT-DR has a performance 
exceeding that of RF in 12/12 drugs, that of KOVER, 
LR-l2, and SVM-l2 in 9/12 drugs, that of LR-l1 in 8/12 
drugs. SVM-l1 is the only competitive model, whose per-
formance it only exceeds in 5/12 drugs, although it does 
obtain a marginally better balanced accuracy on average 
(85.7% vs. 85.3%).
INGOT‑DR produces interpretable models
INGOT-DR produces predictive models in the form 
of disjunctive (logical-OR) rules over the presence of 
specific SNPs, as explained in “From group testing to 
interpretable classiffication”. These models are easy to 
understand and interpret. Although KOVER considers 
rules containing both presence and absence of features 
Table 3 Balanced accuracy of all the methods in predicting drug resistance to 12 drugs
Maximum values are shown in bold
Drug INGOT‑DR KOVER LR‑l1 LR‑l2 RF SVM‑l1 SVM‑l2
Isoniazid 0.903 0.898 0.889 0.877 0.801 0.899 0.880
Rifampicin 0.909 0.904 0.923 0.894 0.826 0.920 0.902
Ethambutol 0.809 0.805 0.833 0.816 0.781 0.836 0.835
Pyrazinamide 0.873 0.860 0.862 0.829 0.796 0.841 0.844
Streptomycin 0.826 0.839 0.852 0.840 0.792 0.859 0.847
Kanamycin 0.856 0.864 0.838 0.845 0.805 0.859 0.838
Amikacin 0.843 0.817 0.880 0.853 0.785 0.853 0.851
Capreomycin 0.859 0.826 0.836 0.812 0.764 0.826 0.812
Ethionamide 0.734 0.736 0.715 0.704 0.659 0.740 0.702
Ofloxacin 0.912 0.908 0.909 0.840 0.788 0.914 0.845
Moxifloxacin 0.920 0.834 0.912 0.803 0.82 0.918 0.803
Ciprofloxacin 0.845 0.845 0.780 0.720 0.623 0.774 0.714
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[30], the absence of a SNP is harder to interpret in the 
context of genomics, so we only focus on the presence 
of SNPs here. We note that, by DeMorgan’s law, both 
methods could produce conjunctive (logical-AND) rules 
by training the model on the complement of the feature 
matrix, Ā , and outcome vector, ȳ ; however, we focus on 
disjunctive rules in this paper.
Fig. 1 Sensitivity and specificity of all the methods in predicting drug resistance to 12 drugs
Table 4 Number of SNPs involved in the prediction made by each model for each drug
Drug INGOT‑DR KOVER LR‑l1 LR‑l2 RF SVM‑l1 SVM‑l2
Isoniazid 20 20 1045 62,707 22,336 626 54,630
Rifampicin 20 20 739 63,621 29,373 476 52,732
Ethambutol 20 19 154 53,476 19,864 661 43,094
Pyrazinamide 20 17 114 32,885 9495 428 25,485
Streptomycin 20 13 5804 43,771 23,996 594 40,183
Kanamycin 20 20 2383 20,934 9314 231 18,716
Amikacin 20 19 2252 16,622 7639 212 14,260
Capreomycin 20 20 2103 14,907 7881 234 13,432
Ethionamide 20 20 41 14,791 7777 280 13,551
Ofloxacin 20 17 394 23,206 14,312 265 19,694
Moxifloxacin 12 7 29 11,678 1371 125 10,237
Ciprofloxacin 5 5 18 5448 325 29 4343
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We display the number of SNPs used by the predic-
tive models produced by each method in Table 4. These 
results, combined with those of the previous section, sug-
gest that INGOT-DR is producing the most interpretable 
models without sacrificing predictive accuracy. Although 
KOVER almost always produces shorter rules, they tend 
to not generalize as well to the testing dataset.
For a specific example, we consider the most con-
cise model produced by INGOT-DR—the one for cip-
rofloxacin, a drug in the fluoroquinolone family. This 
Fig. 2 Top k ≤ 20 SNPs chosen by each model, categorized by association with drug resistance
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model has a rule size of 5, and the SNPs used are all in 
the gyrA gene, known to be involved in the resistance to 
fluoroquinolones such as ciprofloxacin in bacteria [62]. 
In this example, INGOT-DR not only identifies the cor-
rect gene, but also selects mutations that are known to 
be associated with fluoroquinolone resistance in MTB—
the selected codons, 90, 91 and 94, are among the codons 
most strongly associated with this type of resistance [63]. 
We state the rule obtained by INGOT-DR below, in a 
standard format specifying the gene, the original amino 
acid, the codon number, and the mutated amino acid.
INGOT‑DR selects many SNPs in genes previously 
associated with drug resistance
Our results demonstrate that the models produced by 
INGOT-DR contain many SNPs in genes previously asso-
ciated with drug resistance in MTB. This suggests that 
INGOT-DR not only makes accurate predictions, but 
that it makes them for the right reason, and could thus 
also be used to prioritize hypotheses about the mecha-
nisms associated with drug resistance.
Figure 2 shows, for each of the models, the top k ≤ 20 
most important SNPs, defined as all the SNPs included 
in a rule by KOVER and INGOT-DR, and the top k SNPs 
by feature importance as defined by SHAP for the other 
models. We categorize each SNP according to the known 
information about its association with resistance to the 
drug of interest in MTB. This categorization is based on a 
list of 183 genes and 19 promoter regions selected out of 
over 4000 MTB genes through a data-driven and consen-
sus-driven process by a panel of experts [64]. We use the 
following categories: 
1. Drug specific association: SNP in a gene or inter-
genic region associated with drug resistance to the 
drug of interest;
2. Known association: SNP in a gene or intergenic 
region associated with drug resistance to any other 
drug;
3. Unknown association: SNP in a gene not known to 
be associated with drug resistance to any drug;
4. Intergenic association: SNP in an intergenic region 
not known to be associated with drug resistance to 
any drug.
We note that for the purposes of this categorization, 
whenever a group of SNPs in perfect LD was selected by 
the model, it was categorized according to the highest 
IFgyrA_A90V ∨ gyrA_S91P ∨ gyrA_D94A
∨ gyrA_D94G ∨ gyrA_D94Y
THEN Resistant to ciprofloxacin
(lowest-numbered) category of any of the SNPs con-
tained in the group. However, very few such SNP groups 
were selected by any of the models, and the absolute 
majority of the ones that were contained SNPs within the 
same gene.
A comparison between the methods based on Fig.  2 
suggests that INGOT-DR and KOVER detect more SNPs 
in regions known to be associated with drug resistance 
than all the other methods, with INGOT-DR detecting 
slightly more such SNPs than KOVER on average, even 
after adjusting for the slightly more concise rules pro-
duced by KOVER relative to INGOT-DR. However, with 
the exception of the most common first-line drugs (top 
row) and the three fluoroquinolones (bottom row), even 
the interpretable methods tend to select more SNPs in 
parts of the genome not known to be associated with 
drug resistance, suggesting the potentially important 
effects of population structure in MTB.
Conclusion
In this paper, we introduced a new approach for creating 
rule-based classifiers. Our method, INGOT-DR, utilizes 
techniques from group testing and Boolean compressed 
sensing, and leverages a 0–1 ILP formulation. It produces 
classifiers that combine high accuracy with interpret-
ability, and are flexible enough to be tailored for specific 
evaluation metrics.
We used INGOT-DR to produce classifiers for pre-
dicting drug resistance in MTB, by setting a minimum 
specificity of 90% and a maximum rule size of 20. We 
tested the classifiers’ predictive accuracy on a variety 
of antibiotics commonly used for treating tuberculosis, 
including five first-line and seven second-line drugs. We 
showed that INGOT-DR produces classifiers with a bal-
anced accuracy exceeding that of other state-of-the-art 
rule-based and machine learning methods. In addition, 
we showed that INGOT-DR produces accurate models 
with a rule size small enough to keep the model under-
standable for human users. Finally, we showed that our 
approach generates insights by successfully identifying 
SNPs associated with drug resistance, as we ascertained 
on the specific example of ciprofloxacin.
We note that the presence of SNPs in perfect linkage 
disequilibrium (LD) [57], i.e. sharing identical presence/
absence patterns, is common in bacteria such as MTB 
whose evolution is primarily clonal [65]. For this reason, 
while the grouping of such SNPs substantially simplifies 
the computational task at hand and makes it tractable, 
ascertaining the exact representative of each group to be 
selected to predict the drug resistance status of an isolate 
remains difficult. The presence of clonal structure within 
bacterial populations is a key challenge for the prediction 
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of drug resistance, which we plan to address in future 
work.
In conclusion, our work has introduced a novel 
method, INGOT-DR, based on group testing tech-
niques, for producing interpretable models of drug 
resistance, which demonstrated a state-of-the-art accu-
racy, descriptive ability, and relevance on an MTB data-
set. In future work, we plan to address the challenges of 
population structure and to extend this framework to 
other bacteria as well as to less frequently used antimi-
crobial drugs. We expect our method to become a key 
part of the drug resistance prediction toolkit for clinical 
and public health microbiology researchers.
Abbreviations
CS: Compressed sensing; FN: False negatives; FP: False positives; GWAS: 
Genome-wide association study; ILP: Integer linear programming; LD: Linkage 
disequilibrium; LR: Logistic regression; MTB: Mycobacterium tuberculosis; RF: 
Random forests; SCM: Set covering machine; SNP: Single-nucleotide polymor-
phism; SVM: Support vector machine; WGS: Whole-genome sequencing.
Acknowledgements
The authors would like to acknowledge Dr. Cedric Chauve, Dr. Ben Adcock and 
Matthew Nguyen for helpful discussions, and the feedback from Dr. Nicholas 
Croucher, Dr. John Lees, Dr. Tim Walker, and Dr. Zamin Iqbal.
Authors’ contributions
HZ has conceptualized and implemented the method, carried out the experi-
ments, and analyzed the results. ND has contributed to the conceptualization 
and implementation. AS and NF have contributed to the data collection, 
preprocessing and analysis. ML and LC have contributed to conceptualizing 
the method, and supervised the research. All the authors have additionally 
contributed to writing or editing the draft and the final version of the manu-
script. All authors read and approved the final manuscript.
Funding
This project was funded by a Genome Canada grant, “Machine learning to 
predict drug resistance in pathogenic bacteria”. LC acknowledges funding 
from the MRC Centre for Global Infectious Disease Analysis (MR/R015600/1), 
funded by the UK Medical Research Council (MRC) and the UK Foreign, Com-
monwealth & Development Office (FCDO) under the MRC/FCDO Concordat 
agreement, and is part of the EDCTP2 program supported by the EU.
Availability of data and materials
The data used in this study is freely available from the ENA and the NCBI. The 
code is freely available on GitHub.
Declarations
Ethics approval and consent to participate
No ethics approval was required for this study.
Consent for publication
All authors have consented to this publication.
Competing interests
The authors declare that they have no competing interests.
Author details
1 School of Computing Science, Simon Fraser University, Burnaby, Canada. 
2 Department of Mathematics, Simon Fraser University, Burnaby, Canada. 
3 Department of Infectious Disease Epidemiology, Imperial College, London, 
UK. 
Received: 11 February 2021   Accepted: 23 July 2021
References
 1. WHO. Antimicrobial resistance: global report on surveillance. Technical 
report. WHO. 2014.
 2. WHO. Global tuberculosis report 2020. Technical report. WHO. 2020.
 3. Raviglione MC, Smith IM. XDR tuberculosis—implications for global 
public health. N Engl J Med. 2007;356(7):656–9.
 4. O’Neill J. Antimicrobial resistance: tackling a crisis for the health and 
wealth of nations. Review on Antimicrobial Resistance. Technical report; 
2014.
 5. Steiner A, Stucki D, Coscolla M, Borrell S, Gagneux S. KvarQ: targeted and 
direct variant calling from fastq reads of bacterial genomes. BMC Genom. 
2014;15:1–12.
 6. Coll F, McNerney R, Preston M, et al. Rapid determination of anti-tuber-
culosis drug resistance from whole-genome sequences. Genome Med. 
2015;7:51.
 7. Bradley P, Gordon N, Walker T, et al. Rapid antibiotic-resistance predictions 
from genome sequence data for Staphylococcus aureus and Mycobacte-
rium tuberculosis. Nat Commun. 2015;6:1–15.
 8. Iwai H, Kato-Miyazawa M, Kirikae T, Miyoshi-Akiyama T. CASTB (the com-
prehensive analysis server for the Mycobacterium tuberculosis complex): 
a publicly accessible web server for epidemiological analyses, drug-
resistance prediction and phylogenetic comparison of clinical isolates. 
Tuberculosis. 2015;95:843–4.
 9. Feuerriegel S, Schleusener V, Beckert P, Kohl TA, Miotto P, Cirillo DM, 
Cabibbe AM, Niemann S, Fellenberg K. PhyResSE: a web tool delineating 
Mycobacterium culosis antibiotic resistance and lineage from whole-
genome sequencing data. J Clin Microbiol. 2015;53(6):1908–14.
 10. Schleusener V, Köser C, Beckert P, et al. Mycobacterium tuberculosis resist-
ance prediction and lineage classification from genome sequencing: 
comparison of automated analysis tools. Sci Rep. 2017;7:1–9.
 11. Yang Y, Niehaus KE, Walker TM, Iqbal Z, Walker AS, Wilson DJ, Peto 
TE, Crook DW, Smith EG, Zhu T, et al. Machine learning for classifying 
tuberculosis drug-resistance from DNA sequencing data. Bioinformatics. 
2018;34(10):1666–71.
 12. Drăghici S, Potter RB. Predicting HIV drug resistance with neural networks. 
Bioinformatics. 2003;19(1):98–107.
 13. Arango-Argoty G, Garner E, Pruden A, Heath LS, Vikesland P, Zhang L. 
DeepARG: a deep learning approach for predicting antibiotic resistance 
genes from metagenomic data. Microbiome. 2018;6(1):1–15.
 14. Chen ML, Doddi A, Royer J, Freschi L, Schito M, Ezewudo M, Kohane IS, 
Beam A, Farhat M. Beyond multidrug resistance: leveraging rare variants 
with machine and statistical learning models in Mycobacterium tuberculo-
sis resistance prediction. EBioMedicine. 2019;43:356–69.
 15. Dorfman R. The detection of defective members of large populations. 
Ann Math Stat. 1943;14(4):436–40.
 16. Foucart S, Rauhut H. A mathematical introduction to compressive sens-
ing. In: Applied and numerical harmonic analysis. New York: Springer; 
2013. https:// books. google. ca/ books? id= zb28B AAAQB AJ.
 17. Eldar YC, Kutyniok G. Compressed sensing: theory and applications. 
Cambridge: Cambridge University Press; 2012.
 18. Duarte MF, Eldar YC. Structured compressed sensing: from theory to 
applications. IEEE Trans Signal Process. 2011;59(9):4053–85.
 19. Lustig M, Donoho D, Pauly JM. Sparse MRI: the application of compressed 
sensing for rapid MR imaging. Magn Resonance Med. 2007;58(6):1182–95.
 20. Herman MA, Strohmer T. High-resolution radar via compressed sensing. 
IEEE Trans Signal Process. 2009;57(6):2275–84.
 21. Mathelin L, Gallivan K. A compressed sensing approach for partial dif-
ferential equations with random input data. Commun Comput Phys. 
2012;12(4):919–54.
 22. Doostan A, Owhadi H. A non-adapted sparse approximation of PDEs with 
stochastic inputs. J Comput Phys. 2011;230(8):3015–34.
 23. Candes EJ, Wakin MB. An introduction to compressive sampling. IEEE 
Signal Process Mag. 2008;25(2):21–30.
 24. Malioutov D, Varshney K. Exact rule learning via Boolean compressed 
sensing. In: International conference on machine learning; 2013. p. 
765–73.
Page 12 of 12Zabeti et al. Algorithms Mol Biol           (2021) 16:17 
 25. Atia GK, Saligrama V. Boolean compressed sensing and noisy group test-
ing. IEEE Trans Inf Theory. 2012;58(3):1880–901.
 26. Aldridge M, Johnson O, Scarlett J, et al. Group testing: an infor-
mation theory perspective. Found Trends Commun Inf Theory. 
2019;15(3–4):196–392.
 27. Doerken S, Avalos M, Lagarde E, Schumacher M. Penalized logistic regres-
sion with low prevalence exposures beyond high dimensional settings. 
PLoS ONE. 2019;14(5):1–14.
 28. Breiman L. Random forests. Mach Learn. 2001;45(1):5–32.
 29. Cortes C, Vapnik V. Support-vector networks. Mach Learn. 1995;20:273–97.
 30. Drouin A, Letarte G, Raymond F, Marchand M, Corbeil J, Laviolette F. 
Interpretable genotype-to-phenotype classifiers with performance 
guarantees. Sci Rep. 2019;9(1):1–13.
 31. Cohen A, Dahmen W, DeVore R. Compressed sensing and best k-term 
approximation. J Am Math Soc. 2009;22(1):211–31.
 32. Walker TM, Kohl TA, Omar SV, Hedge J, Del Ojo Elias C, Bradley P, Iqbal 
Z, Feuerriegel S, Niehaus KE, Wilson DJ, et al. Whole-genome sequenc-
ing for prediction of Mycobacterium tuberculosis drug susceptibil-
ity and resistance: a retrospective cohort study. Lancet Infect Dis. 
2015;15(10):1193–202.
 33. Aldridge M, Baldassini L, Johnson O. Group testing algorithms: bounds 
and simulations. IEEE Trans Inf Theory. 2014;60(6):3671–87.
 34. Natarajan BK. Sparse approximate solutions to linear systems. SIAM J 
Comput. 1995;24(2):227–34.
 35. Malioutov D, Malyutov M. Boolean compressed sensing: LP relaxation for 
group testing. In: 2012 IEEE international conference on acoustics, speech 
and signal processing (ICASSP); 2012. p. 3305–8.
 36. Chen X, Ishwaran H. Random forests for genomic data analysis. Genom-
ics. 2012;99(6):323–9.
 37. Basu S, Kumbier K, Brown JB, Yu B. Iterative random forests to discover 
predictive and stable high-order interactions. Proc Natl Acad Sci. 
2018;115(8):1943–8.
 38. Kouchaki S, Yang Y, Walker TM, Sarah Walker A, Wilson DJ, Peto TE, Crook 
DW, Clifton DA. Application of machine learning techniques to tubercu-
losis drug resistance analysis. Bioinformatics. 2019;35(13):2276–82.
 39. Boser BE, Guyon IM, Vapnik VN. A training algorithm for optimal margin 
classifiers. In: Proceedings of the fifth annual workshop on computational 
learning theory. COLT ’92. New York: Association for Computing Machin-
ery; 1992. p. 144–52.
 40. van Rossum G. Python tutorial. Technical report CS-R9526, Centrum voor 
Wiskunde en Informatica (CWI). Amsterdam; 1995.
 41. Drouin A, Giguère S, Déraspe M, Marchand M, Tyers M, Loo VG, Bourgault 
A-M, Laviolette F, Corbeil J. Predictive computational phenotyping and 
biomarker discovery using reference-free genome comparisons. BMC 
Genom. 2016;17(1):754.
 42. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, 
Blondel M, Prettenhofer P, Weiss R, Dubourg V, et al. Scikit-learn: machine 
learning in Python. J Mach Learn Res. 2011;12:2825–30.
 43. Drouin A. Learn interpretable computational phenotyping models from k
-merized genomic data; 2020. https:// github. com/ aldro 61/ kover.
 44. IBM. IBM ILOG CPLEX optimization studio V12.10.0 documentation. Inter-
national Business Machines Corporation. 2020.
 45. Mitchell S, O’Sullivan M, Dunning I. PuLP: a linear programming toolkit 
for Python. 2011. http:// www. optim izati on- online. org/ DB_ FILE/ 2011/ 09/ 
3178. pdf.
 46. Lougee-Heimer R. The common optimization interface for operations 
research: promoting open-source software in the operations research 
community. IBM J Res Dev. 2003;47(1):57–66. https:// doi. org/ 10. 1147/ rd. 
471. 0057.
 47. Wattam AR, Abraham D, Dalay O, Disz TL, Driscoll T, Gabbard JL, Gillespie 
JJ, Gough R, Hix D, Kenyon R, et al. PATRIC, the bacterial bioinformatics 
database and analysis resource. Nucleic Acids Res. 2014;42(D1):581–91.
 48. Starks AM, Avilés E, Cirillo DM, Denkinger CM, Dolinger DL, Emerson 
C, Gallarda J, Hanna D, Kim PS, Liwski R, et al. Collaborative effort for a 
centralized worldwide tuberculosis relational sequencing data platform. 
Clin Infect Dis. 2015;61(suppl_3):141–6.
 49. Ngo T-M, Teo Y-Y. Genomic prediction of tuberculosis drug-resistance: 
benchmarking existing databases and prediction algorithms. BMC Bioin-
form. 2019;20(1):68.
 50. Deelder W, Christakoudi S, Phelan J, Diez Benavente E, Campino S, 
McNerney R, Palla L, Clark TG. Machine learning predicts accurately Myco-
bacterium tuberculosis drug resistance from whole genome sequencing 
data. Front Genet. 2019;10:922.
 51. Leinonen R, Akhtar R, Birney E, Bower L, Cerdeno-Tárraga A, et al. The 
European nucleotide archive. Nucleic Acids Res. 2011;39:28–31.
 52. Leinonen R, Sugawara H, Shumway M, Collaboration INSD. The sequence 
read archive. Nucleic Acids Res. 2010;39(suppl_1):19–21.
 53. Coll F, McNerney R, Guerra-Assunção JA, Glynn JR, Perdigão JA, Viveiros 
M, Portugal I, Pain A, Martin N, Clark TG. A robust SNP barcode for typing 
Mycobacterium tuberculosis complex strains. Nat Commun. 2014;5:1–5.
 54. Li H. Aligning sequence reads, clone sequences and assembly contigs 
with BWA-MEM. arXiv; 2013.
 55. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abe-
casis G, Durbin R. The sequence alignment/map format and SAMtools. 
Bioinformatics. 2009;25(16):2078–9.
 56. Poplin R, Ruano-Rubio V, DePristo MA, Fennell TJ, Carneiro MO, der Auw-
era GAV, Kling DE, Gauthier LD, Levy-Moonshine A, Roazen D, et al. Scal-
ing accurate genetic variant discovery to tens of thousands of samples. 
bioRxiv. 2017.
 57. San JE, Baichoo S, Kanzi A, Moosa Y, Lessells R, Fonseca V, Mogaka J, Power 
R, de Oliveira T. Current affairs of microbial genome-wide association 
studies: approaches, bottlenecks and analytical pitfalls. Front Microbiol. 
2020;10:3119.
 58. Murdoch WJ, Singh C, Kumbier K, Abbasi-Asl R, Yu B. Interpretable 
machine learning: definitions, methods, and applications. arXiv; 2019.
 59. Saber MM, Shapiro BJ. Benchmarking bacterial genome-wide associa-
tion study methods using simulated genomes and phenotypes. Microb 
Genom. 2020;6(3):000337.
 60. Lundberg SM, Lee S-I. A unified approach to interpreting model predic-
tions. In: Guyon I, Luxburg UV, Bengio S, Wallach H, Fergus R, Vishwana-
than S, Garnett R, editors. Advances in neural information processing 
systems, vol. 30; 2017. p. 4765–74.
 61. Lundberg SM, Erion G, Chen H, DeGrave A, Prutkin JM, Nair B, Katz R, Him-
melfarb J, Bansal N, Lee S-I. From local explanations to global understand-
ing with explainable AI for trees. Nat Mach Intell. 2020;2(1):2522–5839.
 62. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. 
Microbiol Mol Biol Rev. 1997;61(3):377–92.
 63. Avalos E, Catanzaro D, Catanzaro A, Ganiats T, Brodine S, Alcaraz J, Rodwell 
T. Frequency and geographic distribution of gyra and gyrb mutations 
associated with fluoroquinolone resistance in clinical Mycobacterium 
tuberculosis isolates: a systematic review. PLoS ONE. 2015;10(3):0120470.
 64. Miotto P, Tessema B, Tagliani E, Chindelevitch L, et al. A standardised 
method for interpreting the association between mutations and 
phenotypic drug-resistance in Mycobacterium tuberculosis. Eur Respir J. 
2017;50(6):170.
 65. Gagneux S. Ecology and evolution of Mycobacterium tuberculosis. Nat Rev 
Microbiol. 2018;16:202–13.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
